Arcutis Biotherapeutics, INC

Arcutis Biotherapeutics announced the appointment of experienced biopharmaceutical executive Christopher Peetz to its Board of Directors, effective July 15, 2026.

Arcutis Biotherapeutics, Inc. announced the results of its 2026 Annual Meeting of Stockholders, where all three proposals, including director elections and auditor ratification, were approved.

Arcutis Biotherapeutics announced first-quarter 2026 financial results, with net product revenue reaching $105.4 million, driven by strong demand for ZORYVE.

Arcutis Biotherapeutics reported strong Q4 and full-year 2025 financial results, driven by ZORYVE sales growth, positive clinical data, and increased 2026 revenue guidance.

Arcutis Biotherapeutics strengthens its Board with the appointment of Amit Munshi as a Class II director and Compensation Committee chair, following the retirement of founder Bhaskar Chaudhuri.

Arcutis Biotherapeutics announced robust third-quarter 2025 financial results, driven by a 122% surge in ZORYVE net product revenue and new FDA approval for pediatric atopic dermatitis.

Arcutis Biotherapeutics reports significant revenue growth and a return to net income in Q3 2025, driven by strong ZORYVE product sales and strategic approvals.

Arcutis Biotherapeutics significantly boosted product revenue and reduced its net loss in Q2 2025, driven by strong ZORYVE sales and new product approvals.

Arcutis Biotherapeutics' Q1 2025 revenue surged, fueled by robust sales of its ZORYVE cream and foam products, alongside licensing agreement revenues.

Arcutis Biotherapeutics saw a significant increase in revenue in the third quarter of 2024, primarily driven by sales of its ZORYVE product line.

Arcutis Biotherapeutics saw a significant increase in product revenue in the second quarter of 2024, primarily driven by sales of ZORYVE cream and foam.

Arcutis Biotherapeutics filed an amendment to its quarterly report to include a previously omitted Rule 10b5-1 trading plan by a board member.

Arcutis Biotherapeutics reports significant revenue growth for its ZORYVE product line in 2025, driven by expanded indications and commercial launches, despite ongoing net losses and a terminated promotion agreement.

Arcutis Biotherapeutics reports increased product revenue driven by ZORYVE sales, alongside continued investment in research and development for its dermatology pipeline.

Arcutis Biotherapeutics' 2023 annual report details commercial growth of ZORYVE, pipeline progress, and financial challenges including a minimum financing covenant.

Christopher Peetz, a Director of Arcutis Biotherapeutics, Inc., reported multiple transactions in common stock on July 15, 2026.

Howard G. Welgus, a Director of Arcutis Biotherapeutics, Inc., sold 4,730 shares of common stock on July 15, 2026 for $26.91 per share.

Director Sue-Jean Lin sold 4,946 shares of Arcutis Biotherapeutics, Inc. (ARQT) pursuant to a 10b5-1 trading plan.

Director Howard G. Welgus exercised stock options and sold shares of Arcutis Biotherapeutics, Inc. under a 10b5-1 plan.

Director Patrick J. Heron filed an amendment to correct a scrivener's error regarding his indirect beneficial ownership of Arcutis Biotherapeutics shares.

Director Patrick J. Heron was granted 5,778 restricted stock units and 16,667 stock options as part of his annual director compensation.

Arcutis Biotherapeutics has scheduled its 2026 Annual Meeting of Stockholders for June 5, 2026, to address director elections, auditor ratification, and executive compensation.

Arcutis Biotherapeutics, Inc. has filed a definitive proxy statement with the SEC.

Arcutis Biotherapeutics announces its annual stockholders meeting to be held virtually on June 12, 2025, to vote on director elections, auditor ratification, and executive compensation.

Arcutis Biotherapeutics, Inc. files a definitive proxy statement with the SEC.

Arcutis Biotherapeutics announces its annual stockholders meeting to be held virtually on June 14, 2024, to vote on director elections, auditor ratification, and executive compensation.

Frazier Life Sciences and affiliated entities updated their beneficial ownership in Arcutis Biotherapeutics, Inc. via an Amendment No. 7 to their Schedule 13D.

State Street Corporation has reported beneficial ownership of 5.1% of Arcutis Biotherapeutics Inc.'s common stock as of March 31, 2026.

Prudential Financial, Inc. filed an amendment to its Schedule 13G, reporting a 4.3% beneficial ownership stake in Arcutis Biotherapeutics, Inc.

Jennison Associates LLC has reported a 4.0% beneficial ownership in Arcutis Biotherapeutics Inc. common stock as of March 31, 2026.

The Vanguard Group reports zero beneficial ownership in Arcutis Biotherapeutics Inc. following an internal realignment.

Rubric Capital Management LP and David Rosen have disclosed a 6.75% beneficial ownership stake in Arcutis Biotherapeutics, Inc., holding 8,271,577 shares as of December 31, 2025.

Prudential Financial, Inc. has filed an amendment to its Schedule 13G, reporting a beneficial ownership of 5.7% in Arcutis Biotherapeutics, Inc. as of December 31, 2025.